How Traversa was paid
$8.9M in total for fiscal 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Other | Total |
|---|---|---|---|---|---|
| Sergio TraversaChief Executive Officer and Director | $787,787 | $2,103,545 | $4,951,301 | $1,050,000 | $8,892,633 |
| Maged ShenoudaChief Financial Officer | $558,990 | $1,581,644 | $3,450,819 | $500,000 | $6,091,453 |
| Charles EnceChief Accounting and Compliance Officer | $548,990 | $1,119,217 | $3,328,819 | $500,000 | $5,497,026 |
| Paul KellyChief Operating Officer | $499,800 | $1,085,480 | $3,328,819 | $375,000 | $5,289,099 |
What changed and why
- $8.9MSergio Traversa received total compensation of $8,892,633 for 2025, compared to $1,800,723 in the prior year.
- The board previously halted pay increases and bonuses in late 2024 due to clinical setbacks.
- Following a successful turnaround and new asset acquisitions, deferred salary increases and bonuses were approved in 2025.
- Stock option awards and retention compensation contributed significantly to the total executive compensation figures for the year.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.